Measurement of functional anti-meningococcal serogroup A activity using strain 3125 as the target strain for serum bactericidal assay

Clinical and Vaccine Immunology

Volumn 18, Issue 7, 2011, Pages 1108-1117

  Poolman, Jan T ^a   De Vleeschauwer, Isabel ^a   Durant, Nathalie ^a   Devos, Nathalie ^a   Feron, Christiane ^a   Lestrate, Pascal ^a   Weynants, Vincent ^a   Boutriau, Dominique ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; MENINGOCOCCOSIS; NONHUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; STRAIN DIFFERENCE;

ADOLESCENT; AGE FACTORS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; HUMANS; INFANT, NEWBORN; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; SEROLOGIC TESTS; SPECIES SPECIFICITY; VACCINATION; VACCINES, CONJUGATE;

EID: 79960142784     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00549-10     Document Type: Article

References (35)

1. Achtman, M., et al. 1992. A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A. J. Infect. Dis. 165:53-68.
2. Anonymous. 1990. Meningococcal meningitis in the Northern Territory 1990. Commun. Dis. Intell. 18:12-15.
3. Black, S., and P. M. Dull. 2008. MenACWY-CRM, a novel quadrivalent meningococcal conjugate vaccine, is well tolerated and immunogenic in infancy through adolescence [abstract]. In 26th Annu. Meet. European Society for Paediatric Infectious Diseases, (ESPID), 13 to 17 May 2008, Graz, Austria.
4. Borrow, R., N. Andrews, D. Goldblatt, and E. Miller. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568-1573.
5. Gatchalian, S., et al. 2008. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int. J. Infect. Dis. 12:278-288.
6. Gheesling, L. L., et al. 1994. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J. Clin. Microbiol. 32:1475-1482.
7. Greenwood, B. M., et al. 1986. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 80:1006-1007.
8. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
9. Granoff, D. M., J. A. Welsch, and S. Ram. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769.
10. Hitchcock, P. J., and T. M. Brown. 1983. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J. Bacteriol. 154:269-277.
11. Hodgson, A., et al. 2008. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 3:e2159.
12. Jackson, L. A., et al. 2009. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin. Infect. Dis. 49:e1-e10.
13. Jackson, L. A., et al. 2009. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J. 28:86-91.
14. Jones, D. M., et al. 1992. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog. 13:219-224.
15. Kerdpanich, A., et al. 2008. Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated. Int. J. Infect. Dis. 12:88-97.
16. Kim, J. J., et al. 1988. Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis. Infect. Immun. 56:2631-2638.
17. Knuf, M., et al. 2010. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28:744-753.
18. Lin, L. I. 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255-268.
19. Mandrell, R. E., F. H. Azmi, and D. M. Granoff. 1995. Complement-mediated bactericidal activity of human antibodies to poly alpha 2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis. 172:1279-1289.
20. Maslanka, S. E., et al. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156-167.
21. Moran, E. E., B. L. Brandt, and W. D. Zollinger. 1994. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:5290-5295.
22. Norheim, G., et al. 2006. Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J. Clin. Microbiol. 44:861-871.
23. Østergaard, L., E. Lebacq, J. Poolman, G. Maechler, and D. Boutriau. 2009. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27:161-168.
24. Poolman, J. T., C. T. P. Hopman, and H. C. Zanen. 1982. Problems in the definition of meningococcal serotypes. FEMS Microbiol. Lett. 13:339-348.
25. Salih, M. A. M., et al. 1990. Characterization of epidemic and non-epidemic Neisseria meningitidis serogroup A strains from Sudan and Sweden. J. Clin. Microbiol. 28:1711-1719.
26. Sanofi-Pasteur. 2007. Menactra meningococcal (groups A, C, Y MCV4 and W-135) polysaccharide diphtheria toxoid conjugate vaccine product information. Sanofi-Pasteur, Lyon, France.
27. Schneider, M., C. R. M. Exley, S. Ram, R. B. Sim, and C. M. Tang. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240.
28. Scholten, R. J. P. M., et al. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41:236-243.
29. Soriano-Gabarró, M., et al. 2007. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine 25(Suppl. 1):A92-A96.
30. Trotter, C., et al. 2009. Seroprevalence of serum bactericidal antibodies to Neisseria meningitidis serogroup A in Burkina Faso, abstr. P033. In 10th Eur. Meningococcal Dis. Soc. (EMGM) Meeting. Manchester, United Kingdom.
31. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
32. Vermont, C., and G. van den Dobbelsteen. 2002. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol. Med. Microbiol. 34:89-96.
33. World Health Organization. 2006. Recommendations to assure the quality, safety and efficacy of group A meningococcal vaccines. WHO/BS/06.2041. World Health Organization, Geneva, Switzerland.
34. Zollinger, W., and R. Mandrell. 1980. Type-specific antigens of group A Neisseria meningitidis: lipopolysaccharide and heat-modifiable outer membrane proteins. Infect. Immun. 28:451-458.
35. Zollinger, W. D., and R. E. Mandrell. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264.